Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
Adult
Aged
Constipation
/ complications
Cost of Illness
Drug Costs
Europe
Facilities and Services Utilization
Female
Health Care Costs
Hospitalization
/ economics
Humans
Irritable Bowel Syndrome
/ complications
Male
Middle Aged
Office Visits
/ economics
Prospective Studies
Retrospective Studies
Severity of Illness Index
Sick Leave
/ economics
Economic analysis
Europe
Healthcare resource utilisation
IBS
IBS-C
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
07 May 2019
07 May 2019
Historique:
received:
25
01
2019
accepted:
10
04
2019
entrez:
9
5
2019
pubmed:
9
5
2019
medline:
17
5
2019
Statut:
epublish
Résumé
Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastrointestinal and nervous system components. The study aim was to assess the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK). An observational, one year retrospective-prospective (6 months each) study of patients diagnosed in the last five years with IBS-C (Rome III criteria) and moderate to severe disease at inclusion (IBS Symptom Severity Scale score ≥ 175). The primary objective was to assess the direct cost to European healthcare systems. Five hundred twenty-five patients were included, 60% (range: 43.1-78.8%) suffered from severe IBS-C. During follow-up 11.1-24.0% of patients had a hospitalisation/emergency room (ER) visit, median stay range: 1.5-12.0 days and 41.1-90.4% took prescription drugs for IBS-C. 21.4-50.8% of employed patients took sick leave (mean: 11.6-64.1 days). The mean annual direct cost to the healthcare systems was €937.1- €2108.0. The total direct cost (combined costs to healthcare systems and patient) for IBS-C was €1421.7-€2487.1. IBS-C is not a life-threatening condition; however, it has large impact on healthcare systems and society. Direct and indirect costs for moderate to severe IBS-C were high with the largest direct cost driver being hospitalisations/ER visits.
Sections du résumé
BACKGROUND
BACKGROUND
Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastrointestinal and nervous system components. The study aim was to assess the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK).
METHODS
METHODS
An observational, one year retrospective-prospective (6 months each) study of patients diagnosed in the last five years with IBS-C (Rome III criteria) and moderate to severe disease at inclusion (IBS Symptom Severity Scale score ≥ 175). The primary objective was to assess the direct cost to European healthcare systems.
RESULTS
RESULTS
Five hundred twenty-five patients were included, 60% (range: 43.1-78.8%) suffered from severe IBS-C. During follow-up 11.1-24.0% of patients had a hospitalisation/emergency room (ER) visit, median stay range: 1.5-12.0 days and 41.1-90.4% took prescription drugs for IBS-C. 21.4-50.8% of employed patients took sick leave (mean: 11.6-64.1 days). The mean annual direct cost to the healthcare systems was €937.1- €2108.0. The total direct cost (combined costs to healthcare systems and patient) for IBS-C was €1421.7-€2487.1.
CONCLUSIONS
CONCLUSIONS
IBS-C is not a life-threatening condition; however, it has large impact on healthcare systems and society. Direct and indirect costs for moderate to severe IBS-C were high with the largest direct cost driver being hospitalisations/ER visits.
Identifiants
pubmed: 31064345
doi: 10.1186/s12876-019-0985-1
pii: 10.1186/s12876-019-0985-1
pmc: PMC6505116
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Investigateurs
None Bouchoucha
None Ducrotte
None Macaigne
None Mion
None Schneider
Le Sidanier
(L)
None Tardy
Zerbib Andresen
(Z)
None Bischoff
None Jander
None Jung
Thomas Jung
(T)
None Krammer
None Langhorst
None Omankowsky
S Omankowsky
(S)
None Schiefke
None Steuer
None Van der Voort
Martin Luther Krankenhausbetrieb
(ML)
None Von Arnim
None Annese
None Cuomo
None De Angelis
None Di Mario
None Di Stefano
None Matteo
None Ferrini
None Gasbarrini
None Giaccobe
None Marchi
None Marzio
None Repici
None Savarino
None Angós
None Berdier
None Brotons
None Caballero-Plasencia
None Caballero
None Clavé
None Fort
Josep Trueta
(J)
None García
None Gómez
None Martínez
None Perelló
None Rey
None Sánchez-Antolín
None Serra
None Tantinà
None Torán
None Ekesbo
None Hellström
None Kjellström
None Lindberg
None Walter
None Arebi
None Bridger
None Butt
None Emmanuel
None Eugenicos
None Kaushik
None Millar
None Sanders
None Whorwell
Références
Ann Intern Med. 2001 May 1;134(9 Pt 2):860-8
pubmed: 11346322
Pharmacoeconomics. 2002;20(7):455-62
pubmed: 12093301
Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1325-9
pubmed: 12468953
Arch Intern Med. 2003 Apr 28;163(8):929-35
pubmed: 12719202
Am J Gastroenterol. 2004 Jan;99(1):113-21
pubmed: 14687152
Scand J Gastroenterol. 2004 Apr;39(4):336-43
pubmed: 15125465
Aliment Pharmacol Ther. 2004 Aug 15;20(4):459-67
pubmed: 15298641
Aliment Pharmacol Ther. 2005 Sep 1;22(5):373-80
pubmed: 16128674
Dig Dis Sci. 2005 Dec;50(12):2268-75
pubmed: 16416174
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
Dig Liver Dis. 2006 Oct;38(10):717-23
pubmed: 16807154
Aliment Pharmacol Ther. 2006 Jul 15;24(2):183-205
pubmed: 16842448
Clin Ther. 2006 Oct;28(10):1726-35; discussion 1710-1
pubmed: 17157129
Qual Saf Health Care. 2009 Feb;18 Suppl 1:i22-7
pubmed: 19188457
Can Fam Physician. 2009 Feb;55(2):143-8
pubmed: 19221071
Am J Gastroenterol. 2011 Oct;106(10):1813-20
pubmed: 21647206
Am J Gastroenterol. 2011 Oct;106(10):1749-59; quiz 1760
pubmed: 21747417
Aliment Pharmacol Ther. 2012 Feb;35(3):350-9
pubmed: 22176384
Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4
pubmed: 22426087
Clin Exp Gastroenterol. 2012;5:203-12
pubmed: 23162373
Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):913-31
pubmed: 24182611
Aliment Pharmacol Ther. 2013 Dec;38(11-12):1338-46
pubmed: 24206371
Health Policy. 2014 Mar;115(1):1-8
pubmed: 24315493
Aliment Pharmacol Ther. 2014 Feb;39(4):371-84
pubmed: 24433216
J Manag Care Spec Pharm. 2014 Apr;20(4):382-90
pubmed: 24684643
J Med Econ. 2014 Aug;17(8):577-86
pubmed: 24811855
World J Gastroenterol. 2014 Jul 21;20(27):8898-909
pubmed: 25083062
Am Health Drug Benefits. 2014 Aug;7(5):289-97
pubmed: 25237424
Am J Gastroenterol. 2015 Apr;110(4):580-7
pubmed: 25781368
Eur J Health Econ. 2016 Dec;17(9):1091-1100
pubmed: 26728984
Gut. 2017 Jun;66(6):1075-1082
pubmed: 26818616
Gastroenterology. 2016 Feb 18;:null
pubmed: 27144627
Nature. 2016 May 18;533(7603):S107
pubmed: 27191487
Aliment Pharmacol Ther. 1997 Apr;11(2):395-402
pubmed: 9146781
Digestion. 1999 Jan-Feb;60(1):77-81
pubmed: 9892803